Take Home Regulation Page 4098

Page 4098

Federal Register

Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations

(i) Unsupervised or “take-home” use.

To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.

(1) Any patient in comprehensive maintenance treatment may receive a single take-home dose for a day that the clinic is closed for business, including Sundays and State and Federal holidays.

(2) Treatment program decisions on dispensing opioid treatment medications to patients for unsupervised use beyond that set forth in paragraph (i)(1) of this section, shall be determined by the medical director.

  1. Absence of recent abuse of drugs (opioid or nonnarcotic),

    including alcohol;

  2. Regularity of clinic attendance;
  3. Absence of serious behavioral problems at the clinic;
  4. Absence of known recent criminal activity, e.g., drug dealing;
  5. Stability of the patient’s home environment and social relationships;
  6. Length of time in comprehensive maintenance treatment;
  7. Assurance that take-home medication can be safely stored within the patient’s home; and
  8. Whether the rehabilitative benefit the patient derived from decreasing the frequency of clinic attendance outweighs the potential risks of diversion.

(3) Such determinations and the basis for such determinations consistent with the criteria outlined in paragraph (i)(2) of this section shall be documented in the patient’s medical record. If it is determined that a patient is responsible in handling opioid drugs, the following restrictions apply:

  1. During the first 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is limited to a single dose each week and the patient shall ingest all other doses under appropriate supervision as provided for under the regulations in this subpart.
  2. In the second 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is two doses per week.
  3. In the third 90 days of treatment, the take-home supply (beyond that of paragraph (i)(1) of this section) is three doses per week.
  4. In the remaining months of the first year, a patient may be given a maximum 6-day supply of take-home medication.
  5. After 1 year of continuous treatment, a patient may be given a maximum 2-week supply of take-home medication.
  6. After 2 years of continuous treatment, a patient may be given a maximum one-month supply of take-home medication, but must make monthly visits.

(4) No medications shall be dispensed to patients in short-term detoxification treatment or interim maintenance treatment for unsupervised or take-home use.

Similar Posts

  • National Methadone Conference 2001 Sponsored by American Methadone Treatment Association

    Admin 04/07/2023

    Attention: This presentation contains pictures and takes time to download.  Please be patient! Opioid Treatment in the 21st Century: Implementing the Vision St. Louis October 7-10, 2001 Five YEAR PLAN AVAILABLE IN POLICY MAKERS LUNCHEON SECTION   Advocacy Events and Patient Participation NAMA at AMTA Conference 2001 Sunday, October 7th Pre-conference Meeting 9 A.M. to…

  • Membership

    Admin 07/25/2021

    You can mail in your membership or use PayPal and join on line. Mail Download Membership Application  You can download a Membership Application in pdf format. You will need the Adobe Reader to open it and print it. Download Adobe Reader here: Or you can print out a copy from our webpage. Print out a copy…

  • Frameset for Methadone Treatment Discussion

    Admin 01/05/2022

    WELCOME TO “METHADONE SPOKEN HERE” NAMA’s NEW Web Discussion Forum Home This is an on-line discussion forum called Methadone Spoken Here.   The contents frame shows the titles of all articles posted to the discussion. Selecting a title will cause the corresponding article to be loaded into this frame. You may also: Post a new article…

  • Figure 3 The Methadone Molecule

    Admin 05/15/2023

       Contents          The Pharmacology of Opioids  Cont.      Back    Education Series Number 5.1  February 2001 (Revised)  Part 2 continued     Figure 3 The Methadone Molecule.  The two dimensional representation of the methadone molecule is very different from that of morphine. However, molecules are three dimensional and the methadone molecule bends into a structure that is very…

  • Chapters and Affiliates

    Admin 04/20/2022

    Websites, Message Boards, Lists, Discussion Groups, Zines & Newsletters   National Alliance of Methadone Advocates Discussion & Message Board We Speak Methadone National Alliance of Methadone Advocates eAlert Subscribe Here via Email National Alliance of Methadone Advocates NAMA Advocate https://www.methadone.org/nama_advocate.htm National Alliance of Methadone Advocates Archives of The Ombudsman https://www.methadone.org/pubs.html BAMA~NAMA BAMA-MISS NAMA & Dolophinia…

  • Answer two

    Admin 07/20/2022

    FALSE! These are three of the many myths of methadone. Few drugs have been studied as extensively in humans as methadone. Hundreds of thousands of people have been maintained on methadone, many since the treatment was developed over thirty years ago. Methadone and methadone therapy are so tremendously misunderstood (for many reasons) that any study…